Much compelling than the sero-prevalence surveys in patients are, the results of a prospective study of 9699 persons which showed that presence of IgA anti-EBV viral capsid antigen antibodies or neutralizing EBV specific anti-DNase antibodies correlated with subsequent risk for nasopharyngeal carcinoma [19]. The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.